Clinical trials: Renal Cell Cancer Metastatic
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT00796757
- Testing
- bevacizumab [Avastin], interferon alfa-2a
- Where
- 50 sites in Czechia, Estonia and 10 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
This phase II trial is studying how well giving bevacizumab together with interleukin-2 works in treating patients with metastatic kidney cancer.
- Trial name
- NCT00126490
- Testing
- Aldesleukin, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07645690
- Testing
- CLEAR CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Kidney Cancer
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00323791
- Testing
- gemcitabine hydrochloride, imatinib mesylate, gene expression analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Carcinoma, Renal Cell
Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
This local, prospective, multicenter, non-interventional study documents observational data on patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy.
- Trial name
- SANE (NCT01982097)
- Testing
- Sorafenib (Nexavar, BAY 43-9006)
- Where
- Russia
- Volunteers
- 61 people
- Sponsor
- Bayer
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON (NCT07197580)
- Testing
- 177Lu-TLX250
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Renal Cell Carcinoma
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication.
- Trial name
- NCT01613846
- Testing
- Sorafenib+Pazopanib, Pazopanib+Sorafenib
- Where
- 72 sites in Austria, Germany and 1 more
- Volunteers
- 544 people
- Sponsor
- Technical University of Munich
Metastatic Renal Cell Carcinoma
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor…
- Trial name
- NCT00515697
- Testing
- Ramucirumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Metastatic Renal Cell Carcinoma
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed…
- Trial name
- NCT00357760
- Testing
- VEGF Trap
- Where
- 205 sites in United States, Peru
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00003376
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 50 sites in United States
- Volunteers
- 330 people
- Sponsor
- Eastern Cooperative Oncology Group
Renal Cell Carcinoma Recurrent
Study of the Combination of CM082 With Everolimus in Patients With mRCC
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.
- Trial name
- NCT02577458
- Testing
- CM082, Everolimus
- Where
- China
- Volunteers
- 18 people
- Sponsor
- AnewPharma
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00020540
- Testing
- recombinant CD40-ligand, recombinant flt3 ligand
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other…
- Conditions
- Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT04413123
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bradley A. McGregor, MD
Renal Cell Carcinoma
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal…
- Trial name
- NCT04267120
- Testing
- Lenvatinib, Pembrolizumab, Research blood collection
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Kidney Cancer
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
The main purpose of this study is to evaluate the effects of the interleukin-2 given in combination with pembrolizumab. Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™.
- Trial name
- NCT02964078
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Renal Cell Carcinoma Metastatic
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, and maximal tolerated dose (MTD) of the combination of Abemaciclib and Sunitinib administered orally in patients with advanced and metastatic renal cell…
- Trial name
- NCT03905889
- Testing
- Abemaciclib, Sunitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Brown University
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor…
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00002733
- Testing
- aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Renal Cell Carcinoma
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
- Trial name
- NCT01034631
- Testing
- Everolimus, BNC105P
- Where
- 108 sites in United States, Australia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hoosier Cancer Research Network
Renal Cell Carcinoma
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Multi-Center Randomized Open-Label Study of single agent IMO-2055 Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
- Trial name
- NCT00729053
- Testing
- IMO-2055
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Idera Pharmaceuticals, Inc.